Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: Geron is a biopharmaceutical company developing therapeutic products for cancer and degenerative diseases based on telomerase and human embryonic stem cell (hESC) technologies. The company has no approved products and relies on research collaborations and licensing for revenue.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 2006 | 9 Months Ended Sep 30, 2006 | 9 Months Ended Sep 30, 2005 |
|---|---|---|---|
| Total Revenues | $723 | $2,092 | $5,403 |
| Net Loss | $(9,837) | $(28,104) | $(24,632) |
| Net Loss Per Share (Basic/Diluted) | $(0.15) | $(0.43) | $(0.44) |
| Operating Cash Flow | N/A | $(21,002) | $(12,869) |
| Cash and Cash Equivalents | $104,556 | $104,556 | $119,303 |
| Marketable Securities | $69,493 | $69,493 | $N/A (Not listed in 2005 balance sheet) |
| Total Current Assets | $178,141 | $178,141 | $N/A |
| Total Current Liabilities | $5,691 | $5,691 | $N/A |
| Accumulated Deficit | $(397,703) | $(397,703) | $(369,599) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues for the nine months ended September 30, 2006, decreased to $2.1 million from $5.4 million in the prior year period. This was primarily due to a significant drop in license fee revenue ($1.7 million in 2006 vs. $5.3 million in 2005), as the 2005 period included a one-time $4.0 million recognition for the transfer of nuclear transfer intellectual property.
- Increased Operating Expenses: Research and development (R&D) expenses increased to $29.4 million for the nine months of 2006 from $25.5 million in 2005. This increase was driven by higher personnel costs (including $1.6 million in new stock-based compensation), increased manufacturing costs for the telomerase cancer vaccine (GRNVAC1), and clinical/preclinical studies for GRN163L and GRNOPC1.
- Accounting Policy Change: The company adopted SFAS 123R on January 1, 2006, requiring the recognition of stock-based compensation expense. This resulted in an additional $3.3 million expense for the nine months ended September 30, 2006, which was not recognized in the comparable 2005 period.
- Interest Income: Interest and other income increased significantly to $6.4 million for the nine months of 2006 from $2.9 million in 2005, attributed to higher cash balances from a 2005 public offering and higher interest rates.
Guidance, Outlook, and Risks
- Liquidity: Management estimates that existing capital resources, interest income, and equipment financing will fund operations through at least December 2007. However, the company expects to incur additional operating losses and will need to raise substantial additional capital in the future.
- Revenue Outlook: The company expects to recognize approximately $538,000 in revenue for the remainder of 2006 from existing deferred revenue. Future revenues are dependent on new agreements and product sales, which are not expected for several years.
- Development Pipeline:
- GRN163L: Phase 1-2 clinical trials initiated for chronic lymphocytic leukemia and solid tumor malignancies.
- GRNVAC1: Manufacturing process transferred from Duke University to Geron for optimization.
- hESC Programs: Testing six therapeutic cell types in animal models; Phase 1-2 clinical trials expected to begin after successful animal studies.
- Risks:
- Regulatory Approval: No products are approved; success depends on FDA and international regulatory approvals, which are uncertain and costly.
- Intellectual Property: Ongoing patent oppositions in Europe (e.g., with Pharmexa) and reexaminations in the U.S. regarding hESC patents could limit commercial rights.
- Capital Needs: Failure to secure additional funding could force the company to delay or eliminate development programs.
- Stock Volatility: The stock price has historically been volatile, influenced by clinical trial results, regulatory news, and general market conditions.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $174.6 million in cash and marketable securities to fund operations through the projected December 2007 date, considering the high burn rate.
- Revenue Sustainability: Assess the reliance on one-time license fees versus recurring revenue streams, noting the significant drop in license revenue year-over-year.
- Stock-Based Compensation Impact: Review the $3.3 million expense impact from the new SFAS 123R accounting standard and its effect on future net loss calculations.
- Patent Status: Monitor the outcomes of the European patent oppositions with Pharmexa and the U.S. reexamination of hESC patents licensed from WARF.
- Clinical Trial Progress: Track enrollment and safety data for the GRN163L Phase 1-2 trials and the transition of GRNVAC1 manufacturing.